Year: 2019
Type: article
Abstract: BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
Authors: Young Zoon Kim, Chae-Yong Kim, Jaejoon Lim, Kyoung Su Sung, Jihae Lee, Hyuk-Jin Oh, Seok-Gu Kang, Shin-Hyuk Kang, Doo-Sik Kong, Sung Hwan Kim, Se-Hyuk Kim, Se Hoon Kim, Yu Jung Kim, Eui Hyun Kim, In Ah Kim, Ho Sung Kim, Tae Hoon Roh, Jae-Sung Park, Hyun Jin Park, Sang Woo Song, Seung Ho Yang, Wan-Soo Yoon, Hong In Yoon, Soon-Tae Lee, Sea-Won Lee, Youn Soo Lee, Chan Woo Wee, Jong Hee Chang, Tae-Young Jung, Hye Lim Jung, Jae Ho Cho, Seung Hong Choi, Hyoung Soo Choi, Je Beom Hong, Do Hoon Lim, Dong-Sup Chung, KSNO Guideline Working Group
Institutions: Seoul National University, Seoul National University Bundang Hospital, Samsung Changwon Hospital, Sungkyunkwan University, CHA University Bundang Medical Center, CHA University, Dong-A University Hospital, Dong-A University, Ewha Womans University, Ewha Womans University Medical Center, Ewha Womans University Mokdong Hospital, Soonchunhyang University, Soonchunhyang University Hospital Cheonan, Yonsei University, Severance Hospital, Yonsei University Health System, Korea University Anam Hospital, Samsung Medical Center, The Catholic University of Korea St. Vincent's Hospital, Ajou University Hospital, Ajou University, Catholic University of Korea, Asan Medical Center, University of Ulsan, The Catholic University of Korea Seoul St. Mary's Hospital, National Cancer Center, Konkuk University, Konkuk University Medical Center, The Catholic University of Korea Incheon St. Mary's Hospital, Yonsei Cancer Hospital, Seoul National University Hospital, Chonnam National University, Chonnam National University Hwasun Hospital, Kangbuk Samsung Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Seoul National University Bundang Hospital, Chonnam National University, Seoul National University, Sungkyunkwan University, Catholic University of Korea, Seoul National University Hospital, Chonnam National University Hwasun Hospital, Samsung, College of Medicine, Seoul National University, College of Medicine, Catholic University of Korea
OpenAlex ID: W2943973500